Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1 FY 2025 core operating income of €1,294m, growing by […]


3 w.
Technology
ID: 4544810495256420198


Similar News expand_more


Technology
Technology
Science
Technology
Science
Technology
Science
Technology
Science
Science
Science
Technology
Technology
Science
Technology
Science
Science
Science
Technology
Technology
Science
Science
Technology
Science
Technology
Science
Technology
Technology
Science
Economics
Technology
Science
Science
Science
Technology
Technology
Science
Space
Science
Technology
Technology
Science
Science
Military
Technology
Science
Technology
Education
Technology
Popular countries based on strong economic and political relations

Add Watch Country

arrow_drop_down